Blueprint Medicines Corp (NASDAQ:BPMC)
| 66.98 Delayed Data As of Feb 14 |  +3.17 / +4.97%Today’s Change | 60.60 Today|||52-Week Range 102.98 | -16.39% Year-to-Date |
Latest BPMC News | Press Releases
| About to Buy Penny Stocks? Look at These 2 Companies First Feb 14 / MotleyFool.com - Paid Partner Content | Blueprint Medicines (BPMC) Q4 2019 Earnings Call Transcript Feb 14 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 63.81 |
| Today’s open | 63.47 |
| Day’s range | 63.21 - 67.24 |
| Volume | 568,779 |
| Average volume (3 months) | 634,511 |
| Market cap | $3.6B |
Data as of 4:00pm ET, 02/14/2020
Growth & Valuation
| Earnings growth (last year) | -34.76% |
| Earnings growth (this year) | -20.40% |
| Earnings growth (next 5 years) | +23.32% |
| Revenue growth (last year) | +49.39% |
| P/E ratio | NM |
| Price/Sales | 57.61 |
| Price/Book | 7.11 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| MNTAMomenta Pharmaceutic... | +0.24 | +0.76% |
| IMMUImmunomedics Inc | -0.40 | -2.13% |
| CRSPCRISPR Therapeutics ... | -2.32 | -3.99% |
| AXSMAxsome Therapeutics ... | +1.80 | +2.03% |
Data as of 4:00pm ET, 02/14/2020
Financials
| Next reporting date | May 6, 2020 |
| EPS forecast (this quarter) | -$2.16 |
| Annual revenue (last year) | $66.5M |
| Annual profit (last year) | -$347.7M |
| Net profit margin | -522.75% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
